CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Aug. 27, 2025 /PRNewswire/ -- Harbour BioMed ("HBM" or the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology, today announced its interim results for the six months ended June 30, 2025.Dr. Jingsong Wang, Founder, Chairman, and CEO of Harbour BioMed, commented: "In the first half of 2025, Harbour BioMed achieved several significant milestones. D ...

| [Table_EPS] 盈利预测与估值 | 2023A | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | --- | | 营业总收入（百万美元） | 89.63 | 38.10 | 154.08 | 109.53 | 143.50 | | 同比(%) | 118.81 | (57.49) | 304.40 | (28.91) | 31.02 | | 归母净利润（百万美元） | 22.80 | 2.78 | 81.75 | 47.13 | 63.11 | | 同比(%) | 116.61 | (87.81) | 2,842.83 | (42.35) | 33.90 | | EPS-最新摊薄（美元/股） | 0.03 | 0.00 | 0.10 | 0.06 | 0.07 | | P/E（现价&最新摊薄） | 49.25 | 404.18 | 13.73 | 23.82 | 17.79 | 证券研究报告·海外公司深度·药品及生物科技(HS) 和铂医药-B（02142.HK） 全球稀缺抗体平台，In China for globa ...